Moderna (MRNA) is back in focus after a key FDA advisory committee unanimously backed its mRNA-based flu vaccine, mFlusiva, and the company used its Science Day to spotlight a broader mRNA pipeline.

The FDA panel outcome and Science Day roadmap appear to have shifted sentiment sharply, with Moderna’s share price at $79.76 after a 30 day share price return of 54.60% and a 1 year total shareholder return of 161.59%, even though the 3 year and 5 year total shareholder returns remain lower.

If Moderna’s mRNA flu and oncology story has you thinking about where else mRNA and AI are changing healthcare, it could be a good moment to scan 40 healthcare AI stocks.

After a rapid rebound, Moderna is now trading at a sizeable premium to analyst targets while still reporting losses. The key question is whether recent mRNA wins leave meaningful upside on the table or if markets already price in future growth.

Most Popular Narrative: 80.2% Overvalued

Compared with the most followed narrative fair value of $44.25, Moderna’s last close at $79.76 sits well above that anchor, putting the current rally against a much lower modeled baseline.

The dramatic expansion and advancement of Moderna's mRNA pipeline beyond COVID-19, including recent positive late-stage data and upcoming filings for flu, RSV, CMV, oncology, and rare diseases, are likely to diversify the revenue base, capitalize on the rising global burden of infectious and chronic diseases, and materially boost future top-line growth.

Read the complete narrative. Read the complete narrative.

Want to see what kind of revenue climb and margin shift would need to underpin that lower fair value for Moderna? The narrative leans on faster top line expansion, a sharp swing in profitability, and a richer future earnings multiple than the wider biotech sector. Curious how those pieces fit together and what assumptions really sit behind that gap to today’s price?

Result: Fair Value of $44.25 (OVERVALUED)

However, Moderna’s flu and broader vaccine expectations still face execution risk if uptake lags regulatory progress, and ongoing losses of $3,194m highlight funding and profitability pressure.

Next Steps

With sentiment on Moderna leaning cautious, this is a good time to move quickly, test the numbers for yourself, and weigh the 1 key reward.

Looking for more investment ideas beyond Moderna?

If Moderna has sharpened your focus on where to deploy capital next, do not stop here. Widen your search now with a few targeted stock ideas.

• Target potential mispricing by scanning for quality opportunities using the 44 high quality undervalued stocks that match your preferred fundamentals and risk profile.
• Strengthen your income playbook by reviewing the 7 dividend fortresses and see which listed companies currently offer yields that may suit a long term payout focus.
• Reduce portfolio stress by filtering for sturdier businesses using the 74 resilient stocks with low risk scores before the next wave of headlines hits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.